New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 21, 2013
08:08 EDTVRXValeant acquires U.S. rights to Targretin from Eisai for $65M
Eisai and Valeant announced that Valeant has acquired U.S. rights for Targretin capsules and Targretin gel 1% from Eisai for $65M upfront, plus potential contingent payments based on certain milestones. As part of the transaction, which takes effect immediately, Eisai has transferred the New Drug Application for Targretin to Valeant, with Valeant assuming responsibilities for all regulatory obligations associated with the product in the United States. Eisai will retain its rights to Targretin outside of the United States and continue to meet the needs of its distribution partners outside of the United States.
News For VRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 19, 2014
08:05 EDTVRXValeant outlook has improved, says RBC Capital
Subscribe for More Information
December 17, 2014
10:53 EDTVRXAckman says 'will take hard look' at Valeant shares after restrictions end
Subscribe for More Information
December 9, 2014
09:31 EDTVRXZoetis drops after report of Valeant abandoning growth by acquisitions strategy
Subscribe for More Information
06:39 EDTVRXValeant to abandon growth by acquisitions strategy, Reuters says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use